Keryx Biopharmaceuticals  

(Public, NASDAQ:KERX)   Watch this stock  
Find more results for KERX
14.23
+0.23 (1.64%)
Dec 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 14.00 - 14.37
52 week 11.53 - 18.48
Open 14.04
Vol / Avg. 582,406.00/1.21M
Mkt cap 1.31B
P/E     -
Div/yield     -
EPS -1.00
Shares 91.94M
Beta 3.06
Inst. own 84%
Mar 10, 2015
Q4 2014 Keryx Biopharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Dec 11, 2014
Keryx Biopharmaceuticals Inc at Oppenheimer Healthcare Conference
Nov 24, 2014
Keryx Biopharmaceuticals Inc at Brean Capital's Life Sciences Summit Conference
Nov 18, 2014
Keryx Biopharmaceuticals Inc at Stifel Healthcare Conference - Webcast
Nov 17, 2014
Keryx Biopharmaceuticals Inc Annual Shareholders Meeting
Nov 6, 2014
Q3 2014 Keryx Biopharmaceuticals Inc Earnings Release
Nov 6, 2014
Q3 2014 Keryx Biopharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -13784.77% -667.60%
Operating margin -13827.34% -672.61%
EBITD margin - -671.84%
Return on average assets -104.92% -117.81%
Return on average equity -126.94% -167.22%
Employees 41 -
CDP Score - -

Address

750 LEXINGTON AVENUE
NEW YORK, NY 10022
United States - Map
+1-212-5315965 (Phone)
+1-212-5315961 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Keryx Biopharmaceuticals, Inc. (Keryx) is focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease. The Company is developing KRX-0502, an investigational, ferric citrate, oral compound that binds to phosphate. Under the name Zerenex, KRX-0502 has completed a United States-based Phase III clinical program for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.

Officers and directors

Michael P. Tarnok Independent Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Ron Bentsur Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
James F. Oliviero III Chief Financial Officer, Treasurer, Corporate Secretary
Age: 38
Bio & Compensation  - Reuters
Gregory P. Madison Chief Operating Officer, Executive Vice President
Age: 46
Bio & Compensation  - Reuters
Brian R. Adams Vice President, General Counsel
Bio & Compensation  - Reuters
Thomas M. Edwards Vice President - US Sales
Bio & Compensation  - Reuters
Abraham Ceesay Vice President of Marketing
Bio & Compensation  - Reuters
Daniel W. Olmstead Vice President - Payer Access
Bio & Compensation  - Reuters
Amit Sharma M.D. Vice President - Medical Affairs
Bio & Compensation  - Reuters
Amy B. Sullivan Vice President - Corporate Development and Public Affairs
Bio & Compensation  - Reuters